文献速递脑血管病

后循环与前循环轻型卒中或短暂性脑缺血发作的卒中复发及抗血小板治疗比较

Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack.
PubMed 文献 · Stroke · 2023-02-15

基于CHANCE-2试验(中国202个中心,2019年9月至2021年3月)的亚组分析,纳入4168例弥散加权成像阳性的轻型卒中或短暂性脑缺血发作患者,比较后循环梗死(PCI)与前循环梗死(ACI)的90天卒中复发风险及替格瑞洛-阿司匹林与氯吡格雷-阿司匹林的疗效差异。结果显示PCI与ACI的卒中复发风险相似(7.4% vs 8.3%;校正HR 1.01,95%CI 0.79-1.29;P=0.94),替格瑞洛-阿司匹林在两组均显著降低卒中复发风险(PCI组HR 0.59,95%CI 0.40-0.89,P=0.01;ACI组HR 0.65,95%CI 0.50-0.85,P=0.002),无梗死部位与治疗的交互作用(交互P=0.92)。

要点

  • 后循环与前循环梗死患者90天卒中复发风险相似(7.4% vs 8.3%;校正HR 1.01,95%CI 0.79-1.29;P=0.94)。
  • 替格瑞洛-阿司匹林较氯吡格雷-阿司匹林显著降低两组卒中复发风险(PCI组HR 0.59;ACI组HR 0.65)。
  • PCI与ACI患者严重或中度出血风险相似(P=0.19),但替格瑞洛-阿司匹林组任何出血风险增加。

核心结论

  • 在轻型卒中或短暂性脑缺血发作患者中,后循环梗死与前循环梗死的卒中复发风险相似。
  • 替格瑞洛-阿司匹林在降低后循环梗死和前循环梗死患者90天内卒中风险方面均优于氯吡格雷-阿司匹林。

研究设计与样本

  • 本研究为CHANCE-2试验(替格瑞洛或氯吡格雷联合阿司匹林治疗高危急性非致残性脑血管事件II)的亚组分析,该试验为双盲设计,在中国202个中心开展,时间范围为2019年9月至2021年3月。
  • 纳入弥散加权成像阳性的患者,根据弥散加权成像高信号病灶分为后循环梗死组和前循环梗死组。
  • 本亚组分析共纳入4168例患者,其中后循环梗死1427例,前循环梗死2741例。
  • 主要疗效结局为90天内新发卒中,主要安全结局为90天内严重或中度出血。

主要发现

  • 90天随访期间,后循环梗死组与前循环梗死组的卒中复发风险相似(7.4% vs 8.3%;校正风险比1.01,95%CI 0.79-1.29;P=0.94)。
  • 与氯吡格雷-阿司匹林相比,替格瑞洛-阿司匹林显著降低后循环梗死组的卒中复发风险(风险比0.59,95%CI 0.40-0.89;P=0.01)。
  • 与氯吡格雷-阿司匹林相比,替格瑞洛-阿司匹林显著降低前循环梗死组的卒中复发风险(风险比0.65,95%CI 0.50-0.85;P=0.002)。
  • 梗死部位与治疗之间无交互作用(交互作用P=0.92)。
  • 后循环梗死组与前循环梗死组的严重或中度出血风险相似(P=0.19)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unclear whether infarct location affects stroke recurrence after index ischemic stroke. We aimed to compare the risk of stroke recurrence and the responses to dual antiplatelets with ticagrelor-aspirin versus clopidogrel-aspirin between patients with posterior circulation infarct (PCI) and those with anterior circulation infarct (ACI) after minor stroke or transient ischemic attack. METHODS: Data were obtained from the double-blind CHANCE-2 trial (Ticagrelor or Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II), which was conducted across 202 centers in China from September 2019 to March 2021. Patients with positive diffusion-weighted imaging were included and classified into PCI and ACI groups according to the hyperintense lesions on diffusion-weighted imaging. The primary efficacy and safety outcomes were a new stroke and severe or moderate bleeding within 90 days, respectively. RESULTS: A total of 4168 patients were included in this substudy, with 1427 PCI and 2741 ACI. During the 90-day follow-up, the risk of stroke recurrence in patients with PCI was similar to that with ACI (7.4% versus 8.3%; adjusted hazard ratio, 1.01 [95% CI, 0.79-1.29]; P=0.94). In comparison with clopidogrel-aspirin, ticagrelor-aspirin significantly reduced the risk of stroke recurrence in both the PCI (hazard ratio, 0.59 [95% CI, 0.40-0.89]; P=0.01) and ACI groups (hazard ratio, 0.65 [95% CI, 0.50-0.85]; P=0.002). There was no treatment-by-infarct location interaction (P value for interaction, 0.92). The risk of severe or moderate bleeding was similar between PCI and ACI patients (P=0.19). However, the risk of any bleeding increased on ticagrelor-aspirin than clopidogrel-aspirin treatment in PCI and ACI patients (P=0.02 and 0.002, respectively). CONCLUSIONS: Our study demonstrated that stroke recurrence was similar between PCI and ACI in patients with minor stroke or transient ischemic attack. Additionally, ticagrelor-aspirin was superior to clopidogrel-aspirin in reducing the risk of stroke within 90 days in both PCI and ACI patients. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04078737.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Liu H, Jing J, Wang A, et al. Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack. Stroke. 2023. PMID: 36789773. doi:10.1161/STROKEAHA.122.041738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。